Developer docs
API playgroundTry for free, no card

Search company profiles

Pretzel Therapeutics

Full company profile

uuid00005sc

Namestring
Pretzel Therapeutics
Legal namestring
Pretzel Therapeutics, Inc.
Websiteurl
pretzeltx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule and antisense oligonucleotide therapies that target mitochondrial dysfunction to treat rare genetic diseases, metabolic conditions, and neurodegenerative disorders. Founded in 2022 and headquartered in Waltham, Massachusetts, with research facilities in Mölndal, Sweden (GoCo Health Innovation City), the company operates three proprietary platform technologies: (1) genome correction therapeutics that reduce mutated mitochondrial DNA and increase healthy mtDNA levels, (2) genome expression modulation using small molecules acting on enzymes involved in mtDNA replication, transcription, and translation, and (3) mitochondrial quality control via small molecules that modulate mitochondria's built-in quality control machinery.

The lead asset PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG, currently in Phase 1 clinical development for POLG disease and broader mitochondrial DNA depletion syndromes, with demonstrated activity across all POLG mutations tested including the four most common mutations covering approximately 70% of patients. The pipeline also includes a SAMHD1 program (preclinical) and a POLRMT antisense oligonucleotide program (late preclinical) targeting obesity and metabolic disease, supported by a Nature Metabolism publication. Scientific founders include Nobel Laureate Sir John Walker, Claes Gustafsson, Maria Falkenberg, Michal Minczuk, and Nils-Göran Larsson—world-leading academic experts in mitochondrial biology.

The company is pre-revenue with no approved products and no disclosed pricing. Its business model is to advance therapies through clinical trials (Phase 1 ongoing in Australia/U.S., Phase 2 planned for H2 2026) toward regulatory approval with the FDA, EMA, and other health authorities, and to commercialize approved therapeutics through standard pharmaceutical channels—including specialty pharmacies for rare disease indications and broader channels for metabolic and neurodegenerative conditions. Capital has been raised through a $72.5 million Series A led by ARCH Venture Partners and Mubadala Capital (September 2022), a follow-on investment from The Mito Fund (July 2025), and a Parkinson's UK grant (April 2025). The company employs 11–50 staff, executed an acquisition of ROME Therapeutics in January 2026, and pursues its GTM through clinical development partnerships, academic collaborations, and regulatory engagement.

Short descriptiontext

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target mitochondrial dysfunction to treat rare genetic mitochondrial diseases, metabolic conditions including obesity, and neurodegenerative disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mitochondrial therapeutics, rare disease treatments, small molecule drugs, clinical-stage biotechnology, mitochondrial DNA depletion
Industry2 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Mitochondrial Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pretzel Therapeutics is a pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel mitochondrial therapies with its lead program PX578 in Phase 1 clinical development for POLG disorders and mitochondrial DNA depletion syndromes. The company plans to commercialize its therapies upon regulatory approval. Revenue will be generated through sales of approved therapeutics for rare diseases and common conditions such as metabolic diseases and neurodegenerative disorders.

pretzeltx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pretzel Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies that target mitochondrial dysfunction. The company leverages three proprietary platform technologies — genome correction therapeutics (gene-editing tools to reduce mutated mitochondrial DNA and increase healthy mtDNA), genome expression modulation (small molecules acting on enzymes involved in mtDNA replication, transcription, and translation), and mitochondrial quality control (small molecules modulating mitochondria's built-in quality control system) — to address rare mitochondrial DNA depletion syndromes, neurodegenerative diseases, and metabolic conditions including obesity.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pretzel Therapeutics is developing a broad pipeline of first-in-class treatments addressing novel targets within mitochondria for rare and common diseases. The company operates two main therapeutic franchises: (1) the Bioenergetics Restoration Franchise led by PX578 (a first-in-class POLG activator in Phase 1) and the SAMHD1 program (preclinical), targeting rare mitochondrial DNA depletion syndromes and neurodegenerative diseases; and (2) the Bioenergetics Modulation Franchise led by the POLRMT program (late preclinical), targeting metabolic conditions including obesity. The pipeline spans neurological, muscular atrophies, metabolic and rare disease indications.

Product and service3 records
1PX578
CategoryMitochondrial Therapeutics
Description

PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG designed to increase mtDNA levels and address the underlying cause of mitochondrial DNA depletion syndromes (MDDS), including POLG disease. It has demonstrated activity across all tested POLG mutations, including the four most common mutations found in approximately 70% of POLG patients, and is currently in Phase 1 clinical development for rare mtDNA depletion syndromes and broader degenerative diseases.

2POLRMT Program
CategoryMitochondrial Therapeutics
Description

The POLRMT program is the lead in the energetics modulation franchise, targeting mitochondrial RNA polymerase (POLRMT) for the treatment of metabolic conditions including obesity. The program uses a liver-directed antisense oligonucleotide approach to knock down POLRMT, resulting in increased energy expenditure and improved body composition. Currently in late preclinical development.

3SAMHD1 Program
CategoryMitochondrial Therapeutics
Description

The SAMHD1 program is the second target in the energetics restoration franchise. SAMHD1 is a key driver of mtDNA levels and represents a potentially complementary mechanistic approach to POLG activation. Currently in preclinical development.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Co-founder Nils-Göran Larsson is Professor of Mitochondrial Genetics at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet. Research by Larsson published in Nature Metabolism on POLRMT inhibition and metabolic effects forms the scientific basis for the company's POLRMT program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-09
Description

Pretzel's scientific co-founders from the University of Gothenburg collaborated on the Nature publication describing the discovery of novel activators that restore function to mutant mitochondrial DNA polymerases. The research was conducted in collaboration with Pretzel co-founders Claes Gustafsson and Maria Falkenberg from the University of Gothenburg.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-03
Description

Parkinson's UK awarded grant funding to support evaluation of Pretzel's POLG activation mechanism in Parkinson's disease models in collaboration with Dr. Roberta Filograna's lab at the Karolinska Institute, Stockholm, Sweden. This represents a strategic research collaboration to explore POLG activation for Parkinson's disease treatment.

4MRC Mitochondrial Biology Unit, University of Cambridge
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Pretzel co-founders Michal Minczuk and Sir John Walker are associated with the MRC Mitochondrial Biology Unit at University of Cambridge. Sir John Walker, a Nobel Laureate, serves on the Scientific Advisory Board. The MRC Mitochondrial Biology Unit research underlies the company's platform technologies.

pretzeltx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing therapies for rare genetic mitochondrial diseases, with lead asset mavodelpar (REN001) advancing in clinical trials. Closely aligned business model and patient population focus.

2Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage biotech developing mitochondria-targeted therapies for rare diseases including mitochondrial myopathies. Most direct competitor in the mitochondrial disease therapeutic space, with elamipretide (SS-31) advancing in clinical trials.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing small molecules targeting mitochondrial dysfunction for primary mitochondrial diseases and other disorders. Directly comparable in mission and target indications (mitochondrial diseases).

TypeDirect peer
Description

Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial diseases, with KL1333 in late-stage development. Comparable both by indication focus and by Nordic/European research footprint similar to Pretzel's Swedish R&D base.

TypeEmerging player
Description

Clinical-stage company developing mitochondrial cell therapies (autologous mitochondrial transplantation) for mitochondrial diseases. Partial overlap — also targets mitochondrial dysfunction but with a distinct cell-therapy modality.

TypeEmerging player
Description

Clinical-stage French biotech developing drugs for metabolic disorders, including TWYMEEG (imeglimin) for type 2 diabetes, with mitochondrial mechanism of action. Comparable on the metabolic franchise side of Pretzel's pipeline.

TypeBroad incumbent
Description

Japanese big pharma that acquired Mitobridge to build a mitochondrial disease franchise. Broader portfolio but overlapping therapeutic area and substantially greater resources for development and commercialization.

TypeBroad incumbent
Description

Reata developed Skyclarys (omaveloxolone) for Friedreich's ataxia, a mitochondrial disease therapeutic, and was acquired by Biogen. A relevant reference point for a successful rare mitochondrial disease commercial story at scale.

TypeEmerging player
Description

Clinical-stage biotech pursuing rare diseases including mitochondrial and CNS indications. Has overlapping therapeutic interest and comparable small-molecule development approach, though currently focused on different targets.

TypeEmerging player
Description

Biotech developing autophagy- and lysosome-based therapies for rare diseases. Senior Research Advisor Jeff Saunders serves both companies. Adjacent in the broader cellular quality control and rare disease therapeutic space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pretzel Therapeutics

Mitochondrial Therapeuticspretzeltx.com

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target mitochondrial dysfunction to treat rare genetic mitochondrial diseases, metabolic conditions including obesity, and neurodegenerative disorders.

What Pretzel Therapeutics does

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule and antisense oligonucleotide therapies that target mitochondrial dysfunction to treat rare genetic diseases, metabolic conditions, and neurodegenerative disorders. Founded in 2022 and headquartered in Waltham, Massachusetts, with research facilities in Mölndal, Sweden (GoCo Health Innovation City), the company operates three proprietary platform technologies: (1) genome correction therapeutics that reduce mutated mitochondrial DNA and increase healthy mtDNA levels, (2) genome expression modulation using small molecules acting on enzymes involved in mtDNA replication, transcription, and translation, and (3) mitochondrial quality control via small molecules that modulate mitochondria's built-in quality control machinery.

The lead asset PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG, currently in Phase 1 clinical development for POLG disease and broader mitochondrial DNA depletion syndromes, with demonstrated activity across all POLG mutations tested including the four most common mutations covering approximately 70% of patients. The pipeline also includes a SAMHD1 program (preclinical) and a POLRMT antisense oligonucleotide program (late preclinical) targeting obesity and metabolic disease, supported by a Nature Metabolism publication. Scientific founders include Nobel Laureate Sir John Walker, Claes Gustafsson, Maria Falkenberg, Michal Minczuk, and Nils-Göran Larsson—world-leading academic experts in mitochondrial biology.

The company is pre-revenue with no approved products and no disclosed pricing. Its business model is to advance therapies through clinical trials (Phase 1 ongoing in Australia/U.S., Phase 2 planned for H2 2026) toward regulatory approval with the FDA, EMA, and other health authorities, and to commercialize approved therapeutics through standard pharmaceutical channels—including specialty pharmacies for rare disease indications and broader channels for metabolic and neurodegenerative conditions. Capital has been raised through a $72.5 million Series A led by ARCH Venture Partners and Mubadala Capital (September 2022), a follow-on investment from The Mito Fund (July 2025), and a Parkinson's UK grant (April 2025). The company employs 11–50 staff, executed an acquisition of ROME Therapeutics in January 2026, and pursues its GTM through clinical development partnerships, academic collaborations, and regulatory engagement.

Pretzel Therapeutics firmographics

Firmographics
Name
Pretzel Therapeutics
Legal name
Pretzel Therapeutics, Inc.
Website
https://pretzeltx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target mitochondrial dysfunction to treat rare genetic mitochondrial diseases, metabolic conditions including obesity, and neurodegenerative disorders.
Ownership category
akta.pro rank

Pretzel Therapeutics industry classification

Industry
Product category
Mitochondrial Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Mitochondrial therapeutics
  • Rare disease treatments
  • Small molecule drugs
  • Clinical-stage biotechnology
  • Mitochondrial DNA depletion

Where Pretzel Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pretzel Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pretzel Therapeutics is a pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel mitochondrial therapies with its lead program PX578 in Phase 1 clinical development for POLG disorders and mitochondrial DNA depletion syndromes. The company plans to commercialize its therapies upon regulatory approval. Revenue will be generated through sales of approved therapeutics for rare diseases and common conditions such as metabolic diseases and neurodegenerative disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Pretzel Therapeutics product offering

Product offering

Core offering

Pretzel Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies that target mitochondrial dysfunction. The company leverages three proprietary platform technologies — genome correction therapeutics (gene-editing tools to reduce mutated mitochondrial DNA and increase healthy mtDNA), genome expression modulation (small molecules acting on enzymes involved in mtDNA replication, transcription, and translation), and mitochondrial quality control (small molecules modulating mitochondria's built-in quality control system) — to address rare mitochondrial DNA depletion syndromes, neurodegenerative diseases, and metabolic conditions including obesity.

Product overview

Pretzel Therapeutics is developing a broad pipeline of first-in-class treatments addressing novel targets within mitochondria for rare and common diseases. The company operates two main therapeutic franchises: (1) the Bioenergetics Restoration Franchise led by PX578 (a first-in-class POLG activator in Phase 1) and the SAMHD1 program (preclinical), targeting rare mitochondrial DNA depletion syndromes and neurodegenerative diseases; and (2) the Bioenergetics Modulation Franchise led by the POLRMT program (late preclinical), targeting metabolic conditions including obesity. The pipeline spans neurological, muscular atrophies, metabolic and rare disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • PX578 PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG designed to increase mtDNA levels and address the underlying cause of mitochondrial DNA depletion syndromes (MDDS), including POLG disease. It has demonstrated activity across all tested POLG mutations, including the four most common mutations found in approximately 70% of POLG patients, and is currently in Phase 1 clinical development for rare mtDNA depletion syndromes and broader degenerative diseases.
  • POLRMT Program The POLRMT program is the lead in the energetics modulation franchise, targeting mitochondrial RNA polymerase (POLRMT) for the treatment of metabolic conditions including obesity. The program uses a liver-directed antisense oligonucleotide approach to knock down POLRMT, resulting in increased energy expenditure and improved body composition. Currently in late preclinical development.
  • SAMHD1 Program The SAMHD1 program is the second target in the energetics restoration franchise. SAMHD1 is a key driver of mtDNA levels and represents a potentially complementary mechanistic approach to POLG activation. Currently in preclinical development.

Companies that use Pretzel Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Pretzel Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pretzel Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Karolinska InstitutetcoreStrategic or Co-development Partner · 4 November 2025Co-founder Nils-Göran Larsson is Professor of Mitochondrial Genetics at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet. Research by Larsson published in Nature Metabolism on POLRMT inhibition and metabolic effects forms the scientific basis for the company's POLRMT program.
  • University of GothenburgcoreStrategic or Co-development Partner · 9 April 2025Pretzel's scientific co-founders from the University of Gothenburg collaborated on the Nature publication describing the discovery of novel activators that restore function to mutant mitochondrial DNA polymerases. The research was conducted in collaboration with Pretzel co-founders Claes Gustafsson and Maria Falkenberg from the University of Gothenburg.
  • Parkinson's UKmajorStrategic or Co-development Partner · 3 April 2025Parkinson's UK awarded grant funding to support evaluation of Pretzel's POLG activation mechanism in Parkinson's disease models in collaboration with Dr. Roberta Filograna's lab at the Karolinska Institute, Stockholm, Sweden. This represents a strategic research collaboration to explore POLG activation for Parkinson's disease treatment.
  • MRC Mitochondrial Biology Unit, University of CambridgecoreStrategic or Co-development Partner · 1 January 2024Pretzel co-founders Michal Minczuk and Sir John Walker are associated with the MRC Mitochondrial Biology Unit at University of Cambridge. Sir John Walker, a Nobel Laureate, serves on the Scientific Advisory Board. The MRC Mitochondrial Biology Unit research underlies the company's platform technologies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Pretzel Therapeutics competitors and assessment

Company assessment

Direct peers

  • Reneo Pharmaceuticals: Clinical-stage biotech developing therapies for rare genetic mitochondrial diseases, with lead asset mavodelpar (REN001) advancing in clinical trials. Closely aligned business model and patient population focus.
  • Stealth BioTherapeutics: Clinical-stage biotech developing mitochondria-targeted therapies for rare diseases including mitochondrial myopathies. Most direct competitor in the mitochondrial disease therapeutic space, with elamipretide (SS-31) advancing in clinical trials.
  • Khondrion: Clinical-stage pharmaceutical company developing small molecules targeting mitochondrial dysfunction for primary mitochondrial diseases and other disorders. Directly comparable in mission and target indications (mitochondrial diseases).
  • Abliva (formerly NeuroVive Pharmaceutical): Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial diseases, with KL1333 in late-stage development. Comparable both by indication focus and by Nordic/European research footprint similar to Pretzel's Swedish R&D base.

Emerging players

  • Minovia Therapeutics: Clinical-stage company developing mitochondrial cell therapies (autologous mitochondrial transplantation) for mitochondrial diseases. Partial overlap — also targets mitochondrial dysfunction but with a distinct cell-therapy modality.
  • Poxel: Clinical-stage French biotech developing drugs for metabolic disorders, including TWYMEEG (imeglimin) for type 2 diabetes, with mitochondrial mechanism of action. Comparable on the metabolic franchise side of Pretzel's pipeline.
  • Cyclerion Therapeutics: Clinical-stage biotech pursuing rare diseases including mitochondrial and CNS indications. Has overlapping therapeutic interest and comparable small-molecule development approach, though currently focused on different targets.
  • Casma Therapeutics: Biotech developing autophagy- and lysosome-based therapies for rare diseases. Senior Research Advisor Jeff Saunders serves both companies. Adjacent in the broader cellular quality control and rare disease therapeutic space.

Broad incumbents

  • Astellas Pharma (Mitobridge): Japanese big pharma that acquired Mitobridge to build a mitochondrial disease franchise. Broader portfolio but overlapping therapeutic area and substantially greater resources for development and commercialization.
  • Reata Pharmaceuticals (Biogen): Reata developed Skyclarys (omaveloxolone) for Friedreich's ataxia, a mitochondrial disease therapeutic, and was acquired by Biogen. A relevant reference point for a successful rare mitochondrial disease commercial story at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pretzel Therapeutics social profiles

Digital presence

Pretzel Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pretzel Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Pretzel Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pretzel Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pretzel Therapeutics

What does Pretzel Therapeutics do?

Pretzel Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies that target mitochondrial dysfunction. The company leverages three proprietary platform technologies — genome correction therapeutics (gene-editing tools to reduce mutated mitochondrial DNA and increase healthy mtDNA), genome expression modulation (small molecules acting on enzymes involved in mtDNA replication, transcription, and translation), and mitochondrial quality control (small molecules modulating mitochondria's built-in quality control system) — to address rare mitochondrial DNA depletion syndromes, neurodegenerative diseases, and metabolic conditions including obesity.

Is Pretzel Therapeutics a public or private company?

Pretzel Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pretzel Therapeutics founded?

Pretzel Therapeutics was founded in 2022. It employs 51 to 100 people.

Where is Pretzel Therapeutics based?

Pretzel Therapeutics is headquartered in Boston, United States, in the North America region.

How does Pretzel Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Pretzel Therapeutics's main competitors?

Direct peers on record are Reneo Pharmaceuticals, Stealth BioTherapeutics, Khondrion and Abliva (formerly NeuroVive Pharmaceutical). Emerging players are Minovia Therapeutics, Poxel, Cyclerion Therapeutics and Casma Therapeutics. Broad incumbents are Astellas Pharma (Mitobridge) and Reata Pharmaceuticals (Biogen).

Does Pretzel Therapeutics have an API?

No public API is recorded for Pretzel Therapeutics.

What industry is Pretzel Therapeutics in?

Pretzel Therapeutics's product category is Mitochondrial Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial DisordersPretzel Therapeutics announced the FDA granted Fast Track Designation to PX578 for POLG-mediated primary mitochondrial disorders. The company plans to initiate the POLARIS Phase 2 study in adult patients in late 2026. The designation supports ongoing FDA engagement and potential expedited review.BioSpacePretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial DisordersPretzel Therapeutics announced the FDA granted Fast Track Designation to PX578 for POLG-mediated primary mitochondrial disorders. The company plans to initiate the Phase 2 POLARIS study in late 2026, following a Phase 1 healthy volunteer study. The designation supports more frequent FDA interactions and expedites review.FinancialContent Business PageArticles from Pretzel Therapeutics, Inc.Pretzel Therapeutics said the FDA cleared its Investigational New Drug application to begin a first-in-patient clinical trial of PX578, its lead candidate for mitochondrial disease. The Phase 2 POLARIS study will test the drug in adult patients with POLG-mediated mitochondrial disease, for which no disease-modifying treatments exist. The trial follows a Phase 1 healthy volunteer study in New Zealand.FinancialContent Business PagePretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of INDPretzel Therapeutics announced that the FDA cleared its Investigational New Drug application for PX578, a first-in-class small molecule activator of mitochondrial polymerase POLG, allowing a first-in-patient trial. The randomized, double-blind, placebo-controlled POLARIS study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy in adults with POLG-mediated primary mitochondrial disease, with initiation planned for late 2026.MorningstarPretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of INDPretzel Therapeutics received FDA clearance to initiate a Phase 2 trial of PX578 in adults with POLG-mediated primary mitochondrial disease. The randomized, double-blind, placebo-controlled POLARIS study is planned for late 2026, following a successful Phase 1 study in healthy volunteers. The company aims to evaluate safety, tolerability, and clinical efficacy of the first-in-class mitochondrial polymerase activator.Longevity.TechnologyPretzel Therapeutics presents PX578 data supporting POLG disease treatmentPretzel Therapeutics presented preclinical data for its investigational therapy PX578 at the 2026 MDA Clinical and Scientific Conference in Orlando, demonstrating activity across all tested POLG mutations including the four most common mutations affecting roughly 70 percent of patients with the condition. The studies showed that PX578 increased mitochondrial DNA levels, improved cellular respiration and energy production, and improved survival outcomes and liver health markers in multiple in vitro and in vivo disease models. The therapy is currently in a Phase 1 clinical study expected to complete in the first half of 2026, with plans to initiate a Phase 2 trial in individuals with POLG disease in the second half of the year.BioSpacePretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG DiseasePretzel Therapeutics presented preclinical data on PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase POLG, at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Studies across multiple in vitro and in vivo models demonstrated that PX578 increases mtDNA levels, improves cellular respiration and energy production, and shows activity across all POLG mutations tested, including the four most common mutations found in approximately 70% of patients. The company is on track to complete its Phase 1 healthy volunteer study in the first half of 2026 and initiate a Phase 2 clinical trial in the second half of 2026.FierceBiotechPretzel emerges as winner from rise and fall of Rome TherapeuticsPretzel Therapeutics has acquired Rome Therapeutics as a fully owned subsidiary, with Rome having formally wound down its operations following a September announcement of planned layoffs amid challenging market conditions. Rome, a preclinical biotech developing reverse transcriptase inhibitors and tumor antigens, had previously raised $199 million in total funding from investors including Johnson & Johnson and Bristol Myers Squibb, but failed to advance assets to clinical stage. Pretzel's CEO and COO had previously worked at Rome before founding Pretzel in 2022 with a $72.5 million series A, positioning the company to continue Rome's scientific work in new hands.Longevity.TechnologyPretzel Therapeutics presents POLRMT preclinical data at ObesityWeek 2025Pretzel Therapeutics presented preclinical data at ObesityWeek 2025 showing that targeting mitochondrial RNA polymerase (POLRMT) in mouse models resulted in weight loss and metabolic improvements. The study involved a liver-directed antisense oligonucleotide (ASO) that knocked down POLRMT, leading to increased energy expenditure and better body composition.BioSpacePretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025Pretzel Therapeutics presented preclinical data at ObesityWeek 2025 in Atlanta showing that inhibition of mitochondrial RNA polymerase (POLRMT) using a liver-directed antisense oligonucleotide produced significant weight loss and improved metabolic parameters including enhanced energy expenditure and glucose homeostasis in diet-induced obese mouse models. The POLRMT program represents a novel liver-targeted mechanism for treating metabolic conditions including obesity and is currently in late preclinical development. The research builds upon foundational work published in Nature Metabolism by co-founder Nils-Goran Larsson and validates Pretzel's bioenergetics platform approach to targeting mitochondrial biology for metabolic disease.